The most recent trading session ended with Ardmore Shipping (ASC) standing at $12.56, reflecting a -1.64% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq decreased by 0.06%.The shipping company's stock has climbed by 9.5% in the past month, exceeding the Transportation sector's loss of 5.71% and the S&P 500's loss of 2.7%.Investors will be eagerly watching for the perf ...

In the latest market close, Ardmore Shipping (ASC) reached $12.34, with a -0.72% movement compared to the previous day. This change lagged the S&P 500's daily gain of 1.26%. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.77%.Coming into today, shares of the shipping company had gained 9.04% in the past month. In that same time, the Transportation sector lost 7.19%, while the S&P 500 lost 2.82%.Investors will be eagerly watching for the performance of Ardmore Shipping ...

Ardmore Shipping (ASC) ended the recent trading session at $11.99, demonstrating a +0.17% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.11%. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq lost 1.49%.Shares of the shipping company have appreciated by 5% over the course of the past month, outperforming the Transportation sector's loss of 6.43% and the S&P 500's gain of 0.4%.The investment community will be paying close attention t ...

For almost a decade, I held research analyst positions in various investment firms, mostly in Toronto. In the summer of 2021, I left the city and moved into a yurt I built in the boreal forest. I went from living in downtown Toronto to living alone in the woods approximately 100km away from the closest paved road or grocery store.Self-sufficiency does not exist, as I replaced my relationships with grocery stores and utility providers with natural ecosystems and, ultimately, with God. Knowing that I am able ...

In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous (SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), showing an average total body weight reduction of 36.2% compared to 23.1%, a 56.7% greater reduction in body weight compared to semaglutide monotherapy. Human equivalent dose of ASC47 low dose 1 (3 mg/kg, SQ, once every f ...

Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.The published data showed that fol ...

Note: I previously covered Ardmore Shipping (NYSE: ASC ) in October. In my last note, I discussed the company’s fleet, product tanker market, and financials. I was not excited about average dividends and a lack of buybacks. At that time, Ardmore traded at 73% PNAV. Despite the discountI am a voracious reader and self-taught investor. In the past, I was an accountant in the maritime industry. Now, I am a happy retiree passionate about writing and financial markets. As the kids are grown up, I have time to pu ...

Ardmore Shipping Corporation (NYSE: ASC ) is a $500 million maritime transporter that works primarily in transporting chemicals and petroleum products with its fleet of 26 vessels. These include four chartered-in vessels, and range from between 25,000 to 50,000 deadweight tonnes.I specialize in analyzing individual stocks. With a strong educational background in both finance and economics, I’ve developed a deep fascination with the stock market and the potential it offers to investors at all levels. I keep ...

-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.This Phase III clinical trial is a randomized, double-blind, pla ...

Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection, demonstrated a half-life of 21 days, supporting once-monthly administration in patients with obesity In multiple pre-clinical studies using the diet-induced obese (DIO) mouse model, ASC47 demonstrated healthy weight loss (muscle-preserving weight loss) Compared to semaglutide in a head-to-head pre-clinical study using a ...